Business Context and Reporting Period
This Form 8-K is filed by Reneo Pharmaceuticals, Inc. (not Onkure Therapeutics, Inc.) on March 23, 2022. The report serves to announce the Company's financial results for the fourth quarter and the full year ended December 31, 2021, along with recent corporate updates. The Company is an emerging growth company incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol RPHM.
Key Financial Metrics
The provided filing text acts as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for specific financial figures.
Material Changes
The filing text does not contain specific data regarding material changes in financial performance versus prior periods. It only confirms that results for the fourth quarter and year ended December 31, 2021, have been issued.
Guidance, Outlook, and Risks
The filing includes "other recent corporate updates" but does not detail specific guidance, outlook, management commentary, risks, or contingencies within the text provided. The information is furnished and explicitly stated as not being "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the correct registrant name is Reneo Pharmaceuticals, Inc. (RPHM), as the input metadata incorrectly listed Onkure Therapeutics, Inc.
- Review Exhibit 99.1 (the Press Release) to obtain actual revenue, net loss, and cash position figures for Q4 and FY 2021.
- Confirm the status of the "recent corporate updates" mentioned in the press release, as these are not detailed in the 8-K text.
- Note that the financial information in this 8-K is furnished, not filed, and carries different liability standards under the Securities Exchange Act.